Azidothymidine-triphosphate impairs mitochondrial dynamics by disrupting the quality control system

Ryosuke Nomura, Takeya Sato, Yuka Sato, Jeffrey A. Medin, Shigeki Kushimoto, Teruyuki Yanagisawa

ARTICLE INFO
Keywords: Mitochondrial function
Mitochondrial dynamics
Oxidative stress
Metabolites
Oxidative phosphorylation
Cardiomyopathy

ABSTRACT
Highly active anti-retrovirus therapy (HAART) has been used to block the progression and symptoms of human immunodeficiency virus infection. Although it decreases morbidity and mortality, clinical use of HAART has also been linked to various adverse effects such as severe cardiomyopathy resulting from compromised mitochondrial functioning. However, the mechanistic basis for these effects remains unclear. Here, we demonstrate that a key component of HAART, 3'-azido-3'-deoxythymidine (AZT), particularly, its active metabolite AZT-triphosphate (AZT-TP), caused mitochondrial dysfunction, leading to induction of cell death in H9c2 cells derived from rat embryonic myoblasts, which serve as a model for cardiomyopathy. Specifically, treatment with 100 µM AZT for 48 h disrupted the mitochondrial tubular network via accumulation of AZT-TP. The mRNA expression of dynamin-related protein (Drp)1 and the Drp1 receptor mitochondrial fission factor (Mff) was upregulated whereas that of optic atrophy 1 (Opa1) was downregulated following AZT treatment. Increased mitochondrial translocation of Drp1, Mff upregulation, and decreased functional Opa1 expression induced by AZT impaired the balance of mitochondrial fission vs. fusion. These data demonstrate that AZT-TP causes cell death by altering mitochondrial dynamics.

1. Introduction
Mitochondria are double-membrane organelles that play a critical role in cellular homeostasis. As such, mitochondrial quality control must be tightly regulated. Mitochondria are dynamic, mobile organelles that continuously change their size and shape through repeated cycles of fission (which allows the removal of damaged mitochondria) and fusion (to repair damaged components). In addition to morphological changes, mitochondrial dynamics include biogenesis, subcellular localization, and distribution [1,2]. These processes involve GTP hydrolysis and are important for maintaining normal cellular function. Fission is regulated by dynamin-related protein (Drp)1, a homolog of the GTP hydrolyase (GTPase) dynamin that is involved in endocytosis, whereas fusion is mediated by the GTPase dynamin-like proteins mitofusin (Mfn)1 and 2 and optic atrophy (Opa)1. These proteins regulate mitochondrial separation and thus control mitochondrial quality.

Antiretroviral drug combinations such as highly active anti-retrovirus therapy (HAART) have been developed to treat human immunodeficiency virus (HIV) infection. Long-term HAART is associated with adverse effects including myopathy, neuropathy, dyslipidemia, diabetes mellitus, pancreatitis, liver failure, and lipodystrophy [3–5]. The majority of HAART regimens involve nucleoside reverse transcriptase inhibitors (NRTIs) such as 3'-azido 3'-deoxythymidine (AZT) that can cause cardiomyopathy resulting from mitochondrial...
dysfunction, which can in turn worsen therapeutic outcomes [6,7]. Previous studies have shown that AZT causes changes to mitochondrial structure and respiratory chain enzyme activity, thereby reducing ATP levels [8,9].

AZT is a thymidine analog that is converted to an active triphosphate metabolite (AZT triphosphate, AZT-TP) by sequential phosphorylation [10]. Human thymidylate kinase (TMPK) catalyzes the conversion of AZT monophosphate (AZT-MP) to AZT diphosphate (AZT-DP), although the low conversion efficiency results in intracellular accumulation of AZT-MP [11], which is correlated with AZT toxicity [12]. In contrast, although the active metabolite AZT-TP exhibits antitroviral activity, little is known about its toxicity to cells. We previously reported that TMPK mutants with improved AZT-MP conversion activity efficiently produced AZT-TP, the accumulation of which induced apoptosis [13], although the underlying mechanism remains to be elucidated.

To address this issue, the present study investigated the cytotoxicity of AZT-TP using an H9c2 cell model established from rat embryonic myoblasts. We found that AZT-TP caused mitochondrial dysfunction, increased the production of cytotoxic reactive oxygen species (ROS), and impaired the balance of the mitochondrial quality control system.

2. Materials and methods

2.1. H9c2 cell culture

H9c2 rat embryonic myoblasts [14] were obtained from DS-Pharmaceutical (Osaka, Japan) and maintained in the Dulbecco’s modified Eagle medium (DMEM; Wako Pure Chemical Industries, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories GmbH, Pasching, Austria), 100 U/ml of penicillin (Nacalai Tesque, Kyoto, Japan), and 100 µg/ml streptomycin (Nacalai Tesque) in an atmosphere of 37 °C and 5% CO2 at constant humidity.

2.2. Preparation of recombinant lentivirus

We used a procedure for producing vesicular stomatitis virus-glycoprotein-pseudotyped recombinant lentivirus carrying human TMPK cDNA that was previously reported by our group [13,15]. Viral supernatant was harvested 48 h post-transfection and concentrated by ultracentrifugation at 72,500g for 2 h using an SW-28Ti swinging bucket rotor centrifuge (Beckman Coulter, Brea, CA, USA). Concentrated viral particles were resuspended in a small volume of DMEM containing 10% FBS. Viral titer was determined using 293 T cells. The percent expression of transgenes in 293T cells was determined 72 h post-infection by fluorescence-activated cell sorting (FACS) on a FACS Canto II instrument (BD Biosciences, Franklin Lakes, NJ, USA) after staining of the cells with phycoerythrin-labeled mouse monoclonal anti-human cluster of differentiation 19 antibody (BD Biosciences). Data were analyzed with Diva software (BD Biosciences).

2.3. Anti-TMPK antibody preparation

A rabbit polyclonal antibody against human TMPK was commercially generated (Sigma-Aldrich Japan, Tokyo, Japan) against the C-terminal 15 amino acids (199–212: CRTATEKPLGELWK) of human TMPK conjugated with keyhole limpet hemocyanin.

2.4. Viral transduction and analysis of transgene expression by immunoblotting

H9c2 cells were transduced with viral stocks at a multiplicity of infection of 20 in the presence of 8 µg/ml protamine sulfate. Infected cells were cultured for 5 days, and transgene expression was confirmed by western blotting. Cells at 80% confluency were washed three times with chilled phosphate-buffered saline (PBS) composed of 10 mM phosphate buffer (pH 7.4) containing 150 mM NaCl and lysed with chilled radioimmunoprecipitation assay buffer containing a mixture of protease inhibitors (Nacalai Tesque) at 4 °C. The concentration of protein in the cell lysate was quantified with a bicinchoninic acid protein assay kit (Nacalai Tesque). Each sample (10 µg) was resolved by 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane that was probed with rabbit anti-human TMPK antibody (1: 5000) followed by horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin (IgG) (1: 10,000; Cell Signaling Technology, Danvers, MA, USA). Loading of equal amounts of protein was confirmed using a murine anti-glyceroldehyde-3-phosphate dehydrogenase (GAPDH) antibody (1: 5000; Wako Pure Chemical Industries) followed by HRP-conjugated goat antimouse IgG (Cell Signaling Technology). Immunoreactivity was detected with the Immobilon Western Chemiluminescent HRP substrate (EMD Millipore, Billerica, MA, USA), and blots were imaged using a Chemidoc XRS system (Bio-Rad, Hercules, CA, USA) equipped with a charge-coupled device camera controlled by Image Lab software (Bio-Rad).

2.5. Analysis of intracellular metabolites of AZT

The procedure for analyzing intracellular concentrations of AZT metabolites has been previously described [13]. Briefly, cells were incubated with 500 µM AZT for 36 h, then resuspended in 5% (w/v) trichloroacetic acid, disrupted by sonication on ice, and centrifuged at 10,000 × g for 15 min at 4 °C to remove cell debris. The supernatant was neutralized by adding an equal volume of 20% tri-n-octylamine in pentane. The aqueous fraction was analyzed by high-performance liquid chromatography (HPLC).

2.6. Evaluation of AZT sensitivity in TMPK-expressing H9c2 cells

H9c2 cells expressing TMPK cDNA were seeded in 96-well plates (3 × 104/well) in 200 µl of cell culture medium containing increasing concentrations of AZT (0, 0.1, 1, 10, and 100 µM and 1 mM). After 4 days of culture, cell viability was analyzed using the Cell Titer-Glo cell viability assay kit (Promega, Madison, WI, USA).

To evaluate the effect of AZT on induction of apoptosis, cells seeded in 6-well plates (5 × 105/well) were cultured in the absence or presence of 100 µM AZT for 2 days, then stained with allophycocyanin-conjugated Annexin V (Bio Legend, San Diego, CA, USA) according to the manufacturer’s protocol.

2.7. Fluorescence microscopy analysis of mitochondrial morphology in living cells

For live cell imaging of mitochondria, cells were stained with 100 nM MitoTracker Green (Invitrogen, Carlsbad, CA, USA) diluted with culture medium for 30 min at 37 °C, rinsed three times with PBS, and then transferred to a solution of Phenol Red-free DMEM (Wako Pure Chemicals Industries) supplemented with 10% FBS, antibiotics, and 25 mM HEPES-NaOH (pH 7.4). Mitochondrial morphology was analyzed by laser scanning confocal microscopy (LSM780; Zeiss, Oberkochen, Germany). The area of mitochondria was quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA) [16].

2.8. Determination of mitochondrial aspect ratio

Mitochondrial aspect ratio was determined as previously described [17,18]. Briefly, the MitoTracker Green signal in images was changed to a grayscale scale, and a suitable threshold level was set in ImageJ software to distinguish the signal intensities of mitochondria from background noise. The lengths of the major and minor axes of mitochondria were measured using ImageJ. The mitochondrial aspect
ratio was calculated as the ratio of the length of the major axis to that of the minor axis of mitochondria.

2.9. Evaluation of Drp1 translocation to mitochondria

Cells were seeded on glass cover slips and incubated with or without 100 µM AZT for 48 h. Mitochondria were then stained with 100 nM MitoRed (Dojindo Laboratories, Kumamoto, Japan) at 37 °C for 30 min and fixed with 4% formalin in PBS for 15 min at room temperature. To block non-specific binding of antibodies, the specimens were treated with blocking-permeabilization buffer containing 1% bovine serum albumin fraction V (Sigma-Aldrich, St. Louis, MO, USA), 5% normal goat serum (Vector Laboratories, Burlingame, CA, USA), and 0.3% Triton X-100 (Sigma-Aldrich) in PBS for 1 h, followed by rabbit anti-Drp1 antibody (Cell Signaling Technology; 1:50 dilution in blocking permeabilization buffer) at 4 °C for 18 h. Samples were washed three times with PBS and then incubated with CF488A-conjugated goat anti-rabbit immunoglobulin G antibody (Biotium, Fremont, CA, USA; 1:500 dilution in PBS). Cell nuclei were stained with DAPI. Samples were mounted with Prolong Diamond Antifade Mountant (Molecular Probes, Eugene, OR, USA). Images of mitochondria were acquired to determine Drp1 localization using a structured illumination microscope with 100 × CFI-SR Apochromat TIRF objective lens (NA = 1.49) (Nikon, Tokyo, Japan). Drp1 localization in mitochondria was evaluated by calculating the Pearson correlation coefficient using NIS Elements software (Nikon).

2.10. Quantitative real-time PCR

Total RNA was extracted from H9c2 cells using Sepazol reagent (Nacalai Tesque) according to the manufacturer’s protocol. RNA concentration was quantified spectrophotometrically at a wavelength of 260 nm using a Nanodrop spectrophotometer (Nanodrop, Wilmington, DE, USA). cDNA synthesis and quantitative real-time PCR were performed using the ReverTra Ace and qPCR RT kits, respectively (Toyobo Co., Osaka, Japan). Briefly, RNA was reverse transcribed with ReverTra Ace reverse transcriptase according to the manufacturer’s protocol, and PCR was performed using the Thunderbird SYBR qPCR master on an ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Relative expression levels of target genes were calculated with the 2−ΔΔCt method relative to that of GAPDH, which was used as an internal control to correct for the total amount of RNA in each PCR reaction. Primer sequences are shown in Table 1 and were designed using the Primer3 program (National Center for Biotechnology Information, Bethesda, MD, USA).

2.11. Western blot analysis of Drp1, mitochondrial fission factor (Mff), and Opa1 expression in mitochondria

Mitochondria were isolated from cells treated with 100 µM AZT or left untreated for 48 h. The effect of AZT on Drp1 and Opa1 expression was analyzed by western blotting using antibodies against Drp1 (1:1000), Mff (1:1000), and phosphorylated (p-)Drp1 (1:1000) (all from Cell Signaling Technology) and against Opa1 (1:2000; BD Biosciences). Equal protein loading was confirmed using a rabbit antibody against voltage-dependent anion channel (1:1000; Sigma-Aldrich).

2.12. Measurement of mitochondrial oxygen consumption rate (OCR)

H9c2 cells expressing wild-type TMPK (hereafter referred to as WT TMPK) or the TMPK R16GLL mutant (hereafter referred to as mutant TMPK) were cultured in the absence or presence of 100 µM AZT for 24 h. Cells (5 × 104/well) were seeded in five wells of an XF24 cell culture plate (Seahorse Bioscience, North Billerica, MA, USA) and cultured for 24 h with or without 100 µM AZT. To measure mitochondrial OCR, we used the XF Cell Mito Stress Test kit (Seahorse Bioscience) according to the manufacturer’s instructions. Briefly, the medium was changed to XF assay medium (Seahorse Bioscience) and after incubation for 1 h in a non-CO2 incubator at 37 °C, OCR was measured using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience). Cells were sequentially treated as follows: (a) basal respiration levels were monitored without additives; (b) oligomycin (1 µM) was added to reversibly inhibit ATP synthase and oxidative phosphorylation, revealing proton leakage; (c) the mitochondrial uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone (0.3 µM) was added to induce maximal respiration; and (d) the mitochondrial respiration inhibitors rotenone (0.1 µM; a complex I inhibitor) and antimycin A (0.1 µM; a complex III inhibitor) were added to terminate the reaction. OCR was calculated using Seahorse software (Seahorse Bioscience).

2.13. Measurement of mitochondrial inner membrane potential

Cells were treated with 100 µM AZT for 2 days or left untreated, and mitochondrial inner membrane potential was determined by staining with 200 nM of 5′, 5′-6′, 6′-tetrachloro-1′, 3′, 3′-tetrathylbenzimidazolylcarbocyanine iodide (JC-1; Molecular Probes) and measuring the fluorescence intensity by flow cytometry.

2.14. Evaluation of the effect of AZT on ROS production

Generation of mitochondrial ROS was measured by staining cells with dihydrothidium (DHE; Wako Pure Chemicals Industries). Superoxide anion radical converts DHE, a non-fluorescent dye, to the fluorescence-emitting 2-hydroxy ethidium [19]. Briefly, after 2 days of culture with or without 100 µM AZT, cells were incubated with 20 µM DHE for 30 min at 37 °C. The fluorescence intensity of DHE was analyzed by flow cytometry. The change in mean fluorescence intensity of cells in each treatment group is expressed as a percentage of the change in untreated control cells.

2.15. Mitochondrial permeability transition pore (mPTP) opening assay

The opening of the mPTP in H9c2 cells was measured with the calcine-cobalt mPTP assay [20]. Briefly, cells were washed with PBS and incubated with 2 µM calcine-acetoxyethyl ester (calcine-AM, Dojindo Laboratories, Kumamoto, Japan) at 37 °C for 20 min, then washed twice with PBS. The cells were then incubated with 5 mM CoCl2 in PBS for 30 min at 37 °C to quench calcine-AM fluorescence and washed twice with PBS, and fluorescence intensity was measured by flow cytometry.

2.16. Quantification of nuclear (n)DNA and mitochondrial (mt)DNA copy numbers

Cells were treated with AZT for 2 days or left untreated and total DNA was isolated from cells using the SV Genomic DNA Isolation kit

---

### Table 1

| Target gene | Primer sequences |
|-------------|------------------|
| Rat Drp1    | Forward: 5′-ctgacatctgtgacccgat-3′<br>Reverse: 5′-tctattccccttctttttcag-3′ |
| Rat Opa1    | Forward: 5′-cttgggctcttctgacca-3′<br>Reverse: 5′-atccttctgcagcaccaact-3′ |
| Mff         | Forward: 5′-acacctgggtcttctgtctgg-3′<br>Reverse: 5′-gccccactcaccaaatgaga-3′ |
| Mfn2        | Forward: 5′-tctgcttcaccaccttcttgat-3′<br>Reverse: 5′-attatcccgggtgatgtcaa-3′ |
| GAPDH       | Forward: 5′-gcctgcttcaccaccttcttgat-3′<br>Reverse: 5′-gcctgcttcaccaccttcttgat-3′ |

**Legend:**
- Forward and reverse primers are shown to indicate the orientation of the primers.
- Primer sequences are case-sensitive.
- Primer sequences correspond to the DNA strands.
- The primers are designed for specific amplification of the target genes using real-time PCR.
Steady-state levels of mtDNA and nDNA were determined by real-time PCR. The copy number was normalized by calculating the mtDNA/nDNA ratio. Primer sequences are shown in Table 2 and were designed with the Primer3 program.

2.7. Statistical analysis

Data are presented as the mean ± SEM. Statistical analyses were performed using GraphPad Prism v.5 software (GraphPad Inc., La Jolla, CA, USA). One-way analysis of variance with the Bonferroni post-hoc test or Student’s $t$-test was used to evaluate the statistical significance of mean differences, which was set at $P < 0.05$.

3. Results

3.1. Establishment of TMPK-overexpressing H9c2 cells

H9c2 cells were transduced with lentivirus at a multiplicity of infection of 20. We selected TMPK mutants that efficiently converted AZT-MP into AZT-DP with cells expressing WT TMPK serving as a control. Cell lysates were prepared 5 days after transduction and transgene expression was confirmed by western blotting (Fig. 1A, lanes 3 and 4; and Fig. 1B). In contrast, endogenous rat TMPK was detected at lower levels in the parental non-transduced H9c2 cell line (Fig. 1A, lane 1 and Fig. 1B) and transduction of H9c2 cells with mock lentivirus did not increase the expression of endogenous rat TMPK (Fig. 1A, lane 2 and Fig. 1B). Interestingly, higher molecular weight bands were observed for cells expressing mutant as compared to WT TMPK (Fig. 1A, lane 4). The mutant form of TMPK has high catalytic activity for conversion of AZT-MP to AZT-DP [11]; it transiently accepts the $\gamma$-phosphoryl group of ATP to generate an intermediate entity before the $\gamma$-phosphoryl group is transferred to AZT-MP to form AZT-DP. Hence, the higher molecular weight band of TMPK (Fig. 1A, lane 4) in the western blot may represent the intermediate form. WT TMPK-expressing cells showed a single band (Fig. 1A, lane 3).

3.2. Analysis of AZT metabolite accumulation

To confirm the functionality of TMPK expressed in transduced cells, we measured intracellular amounts of AZT metabolites by reverse-phase HPLC. Cells expressing mutant TMPK efficiently converted AZT-MP into AZT-DP and then into AZT-TP, a reaction that was catalyzed by endogenous nucleoside diphosphate kinase (Fig. 2A). To compare the
amounts of AZT metabolites in cells, we calculated the ratio of AZT-TP to AZT-MP by measuring the areas under the curve of AZT-MP and AZT-TP from each chromatogram. Mutant TMPK-expressing cells showed a higher ratio of AZT-TP to AZT-MP than WT TMPK-expressing cells (Fig. 2B). These data demonstrate that AZT-TP accumulates in H9c2 cells expressing mutant TMPK.

3.3. Active AZT metabolites decrease cell viability

To investigate the effect of AZT antimetabolites on cell viability, TMPK-expressing cells were incubated with increasing concentrations of AZT for 48 h and cell viability was assayed based on cellular ATP levels (Fig. 3A). Cells expressing mutant TMPK showed a concentration-dependent decrease in viability in the presence of AZT, with a half-maximal inhibitory concentration of 70 µM. This was not observed in cells expressing WT TMPK and treated with up to 1 mM AZT. In subsequent experiments, cells were incubated with 100 µM AZT for 48 h.

We also evaluated the induction of apoptosis by AZT. Apoptosis was induced to a greater degree in cells expressing mutant but not WT TMPK treated with AZT (161.5 ± 5.88% vs. control, n = 3). Scale bar = 5 µm. B. Mitochondrial area per cell was decreased in mutant TMPK-expressing cells treated with AZT. *P < 0.05 vs. mutant TMPK without AZT; n.s., not significant vs. mutant TMPK without AZT. Data represent mean ± SEM (n = 13). Statistical significance was evaluated by one-way analysis of variance with Bonferroni’s multiple comparison post-hoc test. n.s., not significant vs. mutant TMPK without AZT.

3.4. AZT-TP accumulation causes mitochondrial fragmentation

Mitochondria are highly dynamic organelles that change their morphology depending on cellular demands to maintain their functionality, which is accomplished by the mitochondrial quality control system. We examined the effects of AZT on mitochondrial morphology by confocal microscopic live cell imaging. Mutant TMPK-expressing cells treated with AZT predominantly exhibited fission-like, fragmented mitochondria as compared to the network structure in untreated cells (Fig. 4A). These results indicate that AZT-TP accumulation causes mitochondrial fragmentation. For subsequent analyses of the expression of factors regulating mitochondrial dynamics, we examined mutant TMPK cells treated with AZT because WT TMPK cells did not show obvious changes.

3.5. Expression of the factors regulating mitochondrial dynamics is affected by AZT

Mitochondria form a complex network whose morphology is regulated through fission and fusion by four large GTPase family proteins, including Opa1, Mfn2, and Drp1, which is critical for maintaining...
mitochondrial functions and cellular homeostasis. We examined the effects of AZT on the expression of these proteins by quantitative real-time PCR (Fig. 5) and western blotting (Fig. 6). AZT-TP accumulation caused downregulation of Opa1 (Fig. 5, P = 0.0376, n = 3) and up-regulation of Drp1 (Fig. 5, P = 0.0258, n = 3); furthermore, Mff expression was increased by AZT treatment (Fig. 5, P = 0.0194, n = 3). In contrast, Mfn2 expression was unaffected by AZT (data not shown).

To confirm these findings, we examined the expression levels of Opa1, Drp1, Mff and p-Drp1 by western blotting using isolated mitochondrial fractions prepared from mutant TMPK-expressing cells treated with AZT for 48 h or left untreated. Drp1 mainly exists in a phosphorylated form in the cytoplasm; its translocation to mitochondria is regulated by de-phosphorylation of p-Drp1 by calcineurin [21]. Opa1 was detected as two bands corresponding to the inner mitochondrial membrane-bound long form (Opa1-L, 90 kDa) and soluble short form (Opa1-S, 80 kDa). Opa1-S has been suggested as a mitochondrial fission factor [22]. AZT treatment decreased the ratio of Opa1-L to Opa1-S (Fig. 6A, P = 0.0295) and enhanced the expression of Drp1 (Fig. 6B, P = 0.031). The p-Drp-1/Drp-1 ratio in mitochondria was also reduced (Fig. 6D, P = 0.0432), suggesting that unphosphorylated Drp1 accumulated in mitochondria. Furthermore, the mitochondrial Drp1 receptor Mff was upregulated by AZT treatment (Fig. 6C, P = 0.01). We also explored Drp1 translocation to mitochondria following AZT treatment by immunohistochemistry using an anti-Drp1 antibody (Fig. 6E). After treatment with AZT, mitochondrial localization of Drp1 was increased in mutant TMPK-expressing cells (Fig. 6E). These results demonstrate that accumulation of AZT-TP disrupts the structure of the mitochondrial network by impairing the mitochondrial fission-fusion cycle.

3.6. AZT-TP accumulation impairs mitochondrial OCR

To confirm the effects of AZT on mitochondrial function in WT and mutant TMPK-expressing cells, we evaluated mitochondrial respiration by measuring OCR (Fig. 7A). AZT did not significantly alter basal OCR (Fig. 7B) or proton leakage (Fig. 7C) in cells expressing mutant and WT TMPK. However, the OCR in cells expressing mutant but not WT TMPK and treated with AZT was decreased, as evidenced by the reduced maximal respiratory capacity (Fig. 7D) relative to untreated controls (P < 0.05). These results indicate that the mitochondrial respiration system is damaged by AZT-TP but not by AZT-MP.

3.7. AZT causes collapse of mitochondrial membrane potential

AZT has been shown to cause mitochondrial dysfunction, resulting in myopathy [23]. To investigate the effect of AZT on mitochondrial function, we measured the change in mitochondrial membrane potential caused by AZT in TMPK-expressing cells using JC-1 (Fig. 8A).

Unexpectedly, WT TMPK-expressing cells treated with AZT showed a decrease in mitochondrial membrane potential (Fig. 8A, P = 0.0078). This effect was even more pronounced in cells expressing the mutant kinase (Fig. 8A, P < 0.0001 vs. WT TMPK). These results indicate that the AZT metabolites AZT-MP and AZT-TP are both toxic to mitochondria, and that the latter has greater toxicity.

3.8. AZT-TP accumulation increases ROS production

ROS are mainly produced in mitochondria as a byproduct of respiration; excess ROS impairs cellular functions, leading to cell death. To assess the role of ROS in AZT-induced mitochondrial dysfunction, we measured mitochondrial ROS levels following treatment with 100 µM AZT for 2 days by staining cells with DHE, which reacts with ROS. We found that ROS production was increased by AZT in mutant TMPK-expressing cells (P < 0.0001) as compared to untreated controls (Fig. 8B). In contrast, AZT had no effect on WT TMPK-expressing cells.

3.9. AZT-TP accumulation increases mPTP opening

Cyclophilin D in the mitochondrial matrix is a member of the cyclophilin family of peptidyl prolyl-cis, trans isomerases that regulate protein folding [24,25], and has been reported to be involved in regulating mPTP, which is a Ca2+-dependent increase in the permeability of the mPTP to molecules < 1500 Da that results in decreased mitochondrial membrane potential, mitochondrial swelling, outer membrane rupture, and release of proapoptotic factors. Cyclosporin A is a specific inhibitor of cyclophilin family proteins that blocks mPTP opening. Given our observation that active AZT metabolites induced mitochondrial dysfunction, leading to induction of apoptosis, we examined whether metabolite accumulation increases the probability of mPTP opening. Cells expressing mutant TMPK treated with AZT showed an increase in mPTP opening (Fig. 8C, 132.1% ± 4.78%, n = 3) compared to untreated cells (P = 0.0026), whereas those expressing WT TMPK showed a decrease in mPTP opening in the presence of AZT. These results suggest that accumulation of the active AZT metabolite AZT-TP induces mPTP opening, leading to loss of mitochondrial inner membrane potential.

3.10. AZT-TP accumulation does not affect mtDNA amount

Mitochondria have their own genomes encoding tRNA, rRNA, and protein sequences that maintain organelle functions. We speculated that the impairment of mitochondrial function by AZT treatment in mutant TMPK-expressing cells was due to a proportional reduction in mtDNA content. To test this hypothesis, we estimated mtDNA content by quantitative PCR. Cells were treated with AZT for 2 days or left untreated, and total DNA was isolated from cells; steady-state levels of mtDNA and nDNA were determined by real-time PCR and normalized by calculating the mtDNA/nDNA ratio. The normalized mean mtDNA copy number in both WT and mutant TMPK-expressing cells treated with AZT showed slight but non-significant decreases relative to untreated cells (Fig. 9), suggesting that AZT-TP does not affect the mtDNA content.

4. Discussion

HAART is a drug combination therapy that is used to disrupt the HIV life cycle and reduce morbidity and mortality caused by HIV infection. However, HAART can cause life-threatening clinical manifestations resulting from mitochondrial toxicity, such as myopathy and neuropathy [3–5]. NRTIs are a key component of HAART and are the main cause of mitochondrial toxicity occurring via inhibition of mitochondrial DNA polymerase (pol)-γ, which is essential for mtDNA synthesis [6,7,23]. However, the precise mechanism underlying the mitochondrial toxicity of NRTIs remains to be elucidated.
Fig. 6. Expression of factors related to mitochondrial fission and fusion in H9c2 cells expressing mutant TMPK. A–C. H9c2 cells expressing mutant TMPK were treated with 100 µM AZT (+) or left untreated (−) and changes in (A) the ratio of Opa1-L to Opa1-S and the expression of (B) Drp1 and (C) Mff relative to voltage-dependent anion channel (VDAC) were evaluated by western blotting. D. Mitochondrial translocation of Drp1 was increased by AZT treatment. The ratio of p-Drp1 to Drp1 is shown. Data represent mean ± SEM (n = 3). Statistical significance was evaluated with Student’s t-test. E. Drp1 translocation to mitochondria was increased by treatment with 100 µM AZT, as determined by immunohistochemistry. Data represent mean ± SEM (n = 50). Statistical significance was evaluated with Student’s t-test.
Expression of mutant TMPK in H9c2 cells was previously shown to induce the phosphorylation of AZT-MP to overcome the rate-limiting step in AZT activation [11] and thereby increase AZT-DP and AZT-TP levels. This result is consistent with our previous report [13]. Although mitochondrial dysfunction caused by AZT has been attributed to the accumulation of the intermediate metabolite AZT-MP in cells, we found that AZT-TP was more toxic to H9c2 cells than AZT-MP [13], suggesting that AZT-TP is responsible for AZT toxicity. Based on our findings, we propose that H9c2 cells expressing TMPK are a useful model for examining the cardiotoxicity of AZT.

Mitochondrial DNA replication occurs independently of the cell cycle [26], and its alteration can impair mitochondrial biogenesis and energy production, leading to organ dysfunction [27]. HAART has been linked to the dysregulation of mitochondrial biogenesis [28], whereas NRTIs have

Fig. 7. Evaluation of mitochondrial respiration. A. Representative OCR profiles of H9c2 cells treated with 100 µM AZT or left untreated. After measurement of basal OCR, cells were sequentially incubated with 1 µM oligomycin to measure proton leakage (a); 0.3 µM carbonyl cyanide p-trifluoromethoxyphenylhydrazone to measure maximum respiration capacity (b); and 0.1 µM rotenone and 0.1 µM antimycin A to terminate the reaction (c). ○: WT TMPK without AZT; •: WT TMPK with AZT; △: mutant TMPK without AZT; ▲: mutant TMPK with AZT. Data represent mean ± SEM (n = 5). B. OCR (basal level). C. OCR following oligomycin addition. D. OCR of maximum respiratory capacity. Statistical significance was evaluated by one-way analysis of variance with Bonferroni’s multiple comparison post-hoc test. *P < 0.05 vs. mutant TMPK without AZT.
AZT-TP accumulation caused mitochondrial fragmentation (Fig. 4A) in addition to dysfunction (Fig. 8A). Autophagy is a cellular process in which damaged organelles, including dysfunctional mitochondria in a process known as mitophagy, are engulfed by autophagosomes and delivered to the lysosome for degradation [38]. Stimulation of mitochondrial fission plays an important role in mitochondrial turnover. An imbalance between mitochondrial fission and fusion can affect mitochondrial morphology. Increasing fission while simultaneously suppressing fusion can induce mitophagy. Downregulation of Opa1 [39] or upregulation of Drp1 [40] has been shown to cause mitochondrial fragmentation, a precondition for mitophagy [41,42]; we observed this phenotype upon AZT treatment. The expression of Opa1 was diminished by AZT treatment in H9c2 cells expressing mutant TMPK (Fig. 5); in contrast, the protein levels of both Opal-1 and S in mitochondria were slightly increased (Fig. 6A), although the difference in Opal-1 expression with and without AZT treatment was not significant (data not shown). Additionally, the fission-related molecule Drp1 was upregulated and the ratio of Opal-1 to Opal-S was decreased in mutant TMPK-expressing cells treated with AZT (Fig. 6A, B). We also observed similar changes in the ratio of Opal-1 to Opal-S and in the expression of Drp1 in total cell lysates (Supplemental Fig. 1B, D). These results demonstrate that accumulation of AZT-TP, an active AZT metabolite, alters mitochondrial dynamics to promote mitophagy and alleviate cellular damage caused by excess ROS production from damaged mitochondria. The role of autophagy in AZT-induced mitochondrial dysfunction has been discussed in detail elsewhere (T. Sato et al., manuscript submitted).

Opal mediates mitochondrial fusion to preserve mitochondrial quality including cristae morphology, thereby protecting against cell death [43,44]. Opa1 knockout mice die in utero [45], and Opa1 deficiency causes mitochondrial fragmentation and dysfunction [46]. Mitochondrial Opa1-L is processed by zinc metalloprotease in conjunction with m-AAA protease to generate Opa1-S [47], which causes mitochondrial fragmentation when overexpressed [48]. Various types of stress can also induce the processing of Opa1-L to Opa1-S, leading to mitochondrial dysfunction [49].

Perturbation of the mitochondrial fusion-fusion balance can aggravate ROS-induced tissue injury [50]. Accordingly, we found that increased accumulation of Opal-S by AZT caused mitochondrial fragmentation (Fig. 6A). We also demonstrated that excessive ROS production was induced by AZT-TP accumulation in mutant TMPK-expressing cells (Fig. 8B). These results suggest that excess ROS enhances Opal processing and leads to mitochondrial fragmentation. Agents that scavenge excess ROS could be used to address whether ROS are required for Opal processing.

Given that NRTIs including AZT are a key component of current HAART regimens, minimizing NRTI-induced mitochondrial damage is critical. We recently reported that mitochondrial acid (MA)-5 can rescue cell death caused by severe oxidative stress in human fibroblasts obtained from a patient with mitochondrial disease [51,52]. It is likely that MA-5 restores mitochondrial function impaired by the active AZT metabolite. We are now evaluating the effects of MA-5 on H9c2 cells expressing mutant TMPK and treated with AZT.

In summary, our data indicate that AZT-TP may interfere with the mitochondrial fusion-fusion cycle by increasing ROS production, thereby disrupting the mitochondrial quality control system. The
adverse effects of AZT in patients treated with HAART over the long term should be reconsidered in light of the mitochondrialopathy demonstrated in this study.

Funding sources
This work was supported by a Grant-in-aid for Scientific Research (C) by the Japan Society for the Promotion of Science (JSPS) KAKENHI (grant number 15K08226 to R.N.); JSPS KAKENHI (grant number 23618003 to T.S.); and by a Health and Labour Sciences Research Grant for research on/AIDS from the Ministry of Health and Labour and Welfare (grant number 08046464 to T.S.).

Conflict of interest
The authors declare no conflict of interests.

Author contributions
R.N., T.S., S.K., and T.Y. designed the experiments; R.A.M. provided reagents and technical support; R.N., T.S., and Y.S. analyzed the data; and R.N. and T.S. wrote the paper.

Acknowledgments
The authors thank Drs. Qichao Song, Masaki Saito, and Noriko Toda for discussions and helpful suggestions regarding the data, and the Biomedical Research Core of Tohoku University Graduate School of Medicine and the Biomedical Research Unit of Tohoku University Hospital for their support.

Appendix A. Supplementary material
Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.redox.2017.06.011.

References
[1] S.A. Detmer, D.C. Chan, Functions and dysfunctions of mitochondrial dynamics, Nat. Rev. Mol. Cell Biol. 8 (2007) 870–879.
[2] P. Amati-Bonneau, D. Milea, D. Bonneau, A. Chevrollier, M. Ferre, V. Guillet, N. Ngoen, D. Loiseau, M.A. de Crescenzo, C. Venry, V. Procaccio, G. Lensen, P. Reyner, DPAP-1-associated disorders: phenotypes and pathophysiology, Int. J. Biochem. Cell Biol. 41 (2009) 1855–1865.
[3] M. Naggal, V. Tayal, S. Kumar, U. Gupta, Adverse drug reactions to antiretroviral drugs performed the experiments; J.A.M. provided reagents and technical support; R.N., T.S., and Y.S. analyzed the data; and R.N. and T.S. wrote the paper.

Author contributions
R.N., T.S., S.K., and T.Y. designed the research; R.N., T.S., and Y.S. performed the experiments; J.A.M. provided reagents and technical support; R.N., T.S., and Y.S. analyzed the data; and R.N. and T.S. wrote the paper.

Acknowledgments
The authors thank Drs. Qichao Song, Masaki Saito, and Noriko Toda for discussions and helpful suggestions regarding the data, and the Biomedical Research Core of Tohoku University Graduate School of Medicine and the Biomedical Research Unit of Tohoku University Hospital for their support.

Appendix A. Supplementary material
Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.redox.2017.06.011.

References
[1] S.A. Detmer, D.C. Chan, Functions and dysfunctions of mitochondrial dynamics, Nat. Rev. Mol. Cell Biol. 8 (2007) 870–879.
[2] P. Amati-Bonneau, D. Milea, D. Bonneau, A. Chevrollier, M. Ferre, V. Guillet, N. Ngoen, D. Loiseau, M.A. de Crescenzo, C. Venry, V. Procaccio, G. Lensen, P. Reyner, DPAP-1-associated disorders: phenotypes and pathophysiology, Int. J. Biochem. Cell Biol. 41 (2009) 1855–1865.
[3] M. Naggal, V. Tayal, S. Kumar, U. Gupta, Adverse drug reactions to antiretroviral therapy in AIDS patients at a tertiary care hospital in India: a prospective observational study, Indian J. Med. Sci. 64 (2010) 245–252.
[4] W.T. Tadesse, A.B. Meckonnen, W.H. Tesfaye, Y.T. Tadesse, Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study, BMC Pharmacol. Toxicol. 15 (2014) 32.
[5] A. Carr, J. Miller, M. Law, D.A. Cooper, A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome, AIDS 14 (2000) 725–732.
[6] A. Cosarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[7] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[8] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[9] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[10] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[11] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[12] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[13] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[14] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[15] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[16] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[17] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[18] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[19] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[20] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[21] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[22] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
[23] M.T. Corcuera Pindado, A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, A. Cossarizza, G. Moyle, Antiretroviral nucleoside and nucleotide analogues and mitochondrial DNA, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1493–1504.
A. Tanaka, M.M. Cleland, S. Xu, D.P. Narendra, D.F. Suen, M. Karbowski, R.J. Youle, Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin, J. Cell Biol. 191 (2010) 1367–1380.

G. Twig, A. Elorza, A.J. Molina, H. Mohamed, J.D. Wikstrom, G. Walzer, L. Stiles, S.E. Haigh, S. Katz, G. Las, J. Alroy, M. Wu, B.F. Py, J. Yuan, J.T. Deeney, B.E. Corkey, O.S. Shirihi, Fission and selective fusion govern mitochondrial segregation and elimination by autophagy, EMBO J. 27 (2008) 433–446.

C. Frezza, S. Cipolat, O. Martinis de Britto, M. Micaroni, G.V. Beznoussenko, T. Rudka, D. Bartoli, R.S. Polishuck, N.N. Danial, B. De Strooper, L. Scorrano, OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion, Cell 126 (2006) 177–189.

A. Olichon, E. Guillou, C. Delettre, T. Landes, L. Arnaune-Pelloquin, L.J. Emorine, V. Mils, M. Daloyau, C. Hamel, P. Amati-Bonneau, D. Bonneau, P. Reynier, G. Lenaers, P. Belenguer, Mitochondrial dynamics and disease, OPA1, Biochim. Biophys. Acta 1763 (2006) 500–509.

V.J. Davies, A.J. Hollins, M.J. Pichota, W. Yip, J.R. Davies, K.E. White, P.P. Nicols, M.E. Boulton, Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function, Hum. Mol. Genet. 16 (2007) 1307–1318.

T. Varanita, M.E. Soriano, V. Romanello, T. Zaglia, R. Quintana-Cabrera, M. Semenzato, R. Menabò, V. Costa, G. Civiletto, P. Pesce, C. Viscomi, M. Zeviani, F. Di Lalla, M. Mongillo, M. Sandri, L. Scorrano, The OPA1-dependent mitochondrial cristae remodeling pathway controls atrophic, apoptotic, and ischemic tissue damage, Cell Metab. 21 (2015) 834–844.

M. Kaser, M. Kambacheld, B. Kisters-Weike, T. Langer, Oma1, a novel membrane-bound metalloproteinase in mitochondria with activities overlapping with the m-AAA protease, J. Biol. Chem. 278 (2003) 46414–46423.

N. Ishihara, Y. Fujita, T. Oka, K. Mihara, Regulation of mitochondrial morphology through proteolytic cleavage of OPA1, EMBO J. 25 (2006) 2966–2977.

T. Wai, J. Garcia-Prieto, M.J. Baker, C. Merkwirth, P. Beniñ, P. Rustin, F.J. Rupérez, C. Barbas, B. Ibáñez, T. Langer, Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice, Science 350 (2015) aad0116.

A.S. Gonzalez, M.E. Elguero, P. Finocchietto, S. Holod, L. Romorini, S.G. Miriuka, J.G. Peralta, J.J. Poderoso, M.C. Carreras, Abnormal mitochondrial fusion-fission balance contributes to the progression of experimental sepsis, Free Radic. Res. 48 (2014) 769–783.

T. Suzuki, H. Yamaguchi, M. Kikukato, T. Matsuzaki, A. Matsuo, T. Sato, Y. Oka, S. Watanabe, D. Minaki, D. Saigusa, H. Shimbo, N. Mori, E. Mishima, H. Shima, Y. Akiyama, Y. Takeuchi, A. Yuri, K. Kikuchi, T. Toyohara, C. Suzuki, M. Kohzuki, J. Anzai, N. Mano, S. Kure, T. Yangisawa, Y. Tomioka, M. Toyomizu, S. Ito, H. Osaka, K. Hayashi, T. Abe, Mitochondric acid 5 (MA-5), a derivative of the plant hormone indole-3-acetic acid, improves survival of fibroblasts from patients with mitochondrial diseases, Toboku J. Exp. Med. 236 (2015) 225–232.

T. Suzuki, H. Yamaguchi, M. Kikukato, O. Hashizume, S. Nagaishi, A. Matsuo, T. Sato, T. Kudo, T. Matsuzaki, K. Murayama, Y. Obha, S. Watanabe, S. Kanno, D. Minaki, D. Saigusa, H. Shimbo, N. Mori, A. Yuri, M. Yokoro, E. Mishima, H. Shima, Y. Akiyama, Y. Takeuchi, K. Kikuchi, T. Toyohara, C. Suzuki, T. Ichimura, J. Anzai, M. Kohzuki, N. Mano, S. Kure, T. Yangisawa, Y. Tomioka, M. Toyomizu, K. Tsutsumo, K. Nakada, J.V. Bonventre, S. Ito, H. Osaka, K. Hayashi, T. Abe, Mitochondric acid 5 binds mitochondria and ameliorates renal tubular and cardiac myocyte damage, J. Am. Soc. Nephrol. 27 (2016) 1925–1932.